Literature DB >> 25423640

Preclinical investigations of intravitreal ziv-aflibercept.

João Rafael de Oliveira Dias, Emmerson Badaró, Eduardo Amorim Novais, Daniel Colicchio, Gabrielly Maria Denadai Chiarantin, Mariana Maurício Matioli, Carina Verna, Fernando Marcondes Penha, Nilana Meza Tenório Barros, Carsten H Meyer, Michel Eid Farah, Eduardo Büchele Rodrigues.   

Abstract

BACKGROUND AND
OBJECTIVE: To investigate the retinal safety of intravitreal (IVT) ziv-aflibercept in rabbits.
MATERIALS AND METHODS: Eighteen rabbits were given an IVT injection of ziv-aflibercept (25 mg/mL) or aflibercept (40 mg/mL) and examined by funduscopy, electroretinography (ERG), optical coherence tomography (OCT), light microscopy, and transmission electron microscopy (TEM). Serum, aqueous, and vitreous were obtained afterward for osmolarity analysis. The effect of ziv-aflibercept on human retinal cultured cells (ARPE-19) was assessed by the MTT cell viability assay.
RESULTS: All eyes showed normal funduscopy, OCT, and ERG findings at baseline and 24 hours or 7 days after the procedure. Median baseline serum, vitreous, and aqueous osmolarity remained unchanged. Histology and TEM showed no major anatomic signs of toxicity. No cytotoxic effect was observed in ARPE-19 cells exposed to ziv-aflibercept.
CONCLUSION: IVT injection ziv-aflibercept at a concentration of 25 mg/mL proved to be safe for the rabbit retina. Copyright 2014, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25423640     DOI: 10.3928/23258160-20141118-15

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  12 in total

1.  Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy.

Authors:  Chetan Videkar; Aditya Kapoor; Jay Chhablani; Raja Narayanan
Journal:  BMJ Case Rep       Date:  2015-12-18

2.  Ziv-aflibercept in macular disease.

Authors:  Ahmad M Mansour; Sara I Al-Ghadban; Muhammad H Yunis; Marwan E El-Sabban
Journal:  Br J Ophthalmol       Date:  2015-02-12       Impact factor: 4.638

Review 3.  Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept.

Authors:  João Rafael de Oliveira Dias; Gabriel Costa de Andrade; Eduardo Amorim Novais; Michel Eid Farah; Eduardo Büchele Rodrigues
Journal:  Int J Retina Vitreous       Date:  2016-02-01

4.  Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases.

Authors:  Kamran HodjatJalali; Shiva Mehravaran; Hooshang Faghihi; Hassan Hashemi; Pegah Kazemi; Hadith Rastad
Journal:  J Curr Ophthalmol       Date:  2017-03-11

5.  CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.

Authors:  João Rafael de Oliveira Dias; Gabriel Costa de Andrade; Vinicius Ferreira Kniggendorf; Eduardo Amorim Novais; André Maia; Carsten Meyer; Sung Eun Song Watanabe; Michel Eid Farah; Eduardo Büchele Rodrigues
Journal:  Retina       Date:  2017-08       Impact factor: 4.256

6.  pH of anti-VEGF agents in the human vitreous: low impact of very different formulations.

Authors:  Bianka Sobolewska; Peter Heiduschka; Karl-Ulrich Bartz-Schmidt; Focke Ziemssen
Journal:  Int J Retina Vitreous       Date:  2017-06-26

Review 7.  Overview of Antibody Drug Delivery.

Authors:  Sahar Awwad; Ukrit Angkawinitwong
Journal:  Pharmaceutics       Date:  2018-07-04       Impact factor: 6.321

8.  Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study.

Authors:  Imoro Zeba Braimah; Ernest Kenu; Kwesi N Amissah-Arthur; Stephen Akafo; Kwaku Oppong Kwarteng; Winfried M Amoaku
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

Review 9.  Diabetic macular edema: Evidence-based management.

Authors:  David J Browning; Michael W Stewart; Chong Lee
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

10.  Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding.

Authors:  Julia de Lima Farah; Ronaldo Sano; Ieda Maria Longo Maugéri; Daniela Teixeira; Mayari Eika Ishimura; Gabriela Martins; Lycia M J Mimica; Cely Barreto da Silva; Carsten H Meyer; João Rafael de Oliveira Dias; Gabriel Costa de Andrade; Michel Eid Farah
Journal:  Int J Retina Vitreous       Date:  2018-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.